Regeneron’s Lynozyfic Granted FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
US-based Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) announced that it has received accelerated approval from the...
Sumitomo Pharma’s Xenleta Approved in China for Community-Acquired Pneumonia Treatment
Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for...
BEBT-908 Receives Conditional NMPA Approval for Relapsed/Refractory DLBCL
Guangzhou BeBetter Medicine Technology Co., Ltd’s first-in-class HDAC/PI3Kα dual-targeted inhibitor BEBT-908 has received conditional approval...
Fosun Pharma Subsidiary Launches Co-Developed Biochemical Reagent with Siemens Healthineers
Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Diagnostics (Shanghai) Co.,...
CSPC Pharma Receives NMPA Approval for Hydroxocobalamine in Pediatric MMA Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...
Kanion Pharma and Space Peptides Submit IND for AI-Enabled CCR8 Peptide Inhibitor KYS2301
Chinese partners Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) and Space Peptides jointly announced the...
CR Medical Holdings Partners with Shanghai Haohai Bio in Medical Aesthetics Sector
China Resources Medical Holdings Company Limited has entered into a strategic partnership with Shanghai Haohai...
Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China
China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical...
AstraZeneca CEO Soriot Explores US Stock Listing Move, Potentially Impacting London Exchange
AstraZeneca (AZ, NASDAQ: AZN) CEO Pascal Soriot is exploring plans to move the British pharmaceutical...
Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11
China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice...
Dizal’s Sunvozertinib Receives FDA Accelerated Approval for EGFR Exon20ins NSCLC
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that the U.S. Food and Drug Administration...
Servier’s Voranigo Approved for IDH-Mutant Diffuse Glioma in Beijing
French firm Servier Pharmaceutical plc.’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2)...
Sichuan Biokin’s Iza-bren Meets Primary Endpoint in Phase III NPC Trial
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its Phase III clinical study...
Genrix Bio Receives NMPA Clearance for GR1803 in Relapsed/Refractory Multiple Myeloma
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that it has received clinical trial...
Simcere Pharma’s Suvemcitug Approved by China’s NMPA for Platinum-Resistant Ovarian Cancer
China-based Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that it has received marketing approval...
China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received clinical trial...
Sun-Novo Pharma Collaborates with LeKuang Huilin on STC007 for Post-Abdominal Surgery Pain
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) this week entered into a technology...
AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion
US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...
Changchun GeneScience’s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its...
XtalPi Completes Pre-Seed Investment in Foundry BioSciences to Advance AI-Driven Longevity Therapeutics
Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced the completion of a...